Treatment options for infections caused by carbapenem-resistant gram-negative bacteria

European Infectious Disease

Volumn 6, Issue 1, 2012, Pages 28-34

  Kosmidis, Chris ^a   Poulakou, Garyphalia ^b   Markogiannakis, Antonios ^c   Daikos, George L ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c LAIKO GENERAL HOSPITAL   (Greece)

Author keywords

Acinetobacter; Carbapenem resistant; Enterobacteriaceae; Epidemiology; Multi drug resistance; Nosocomial infections; Pseudomonas; Resistance mechanisms; Treatment

Indexed keywords

AMINOGLYCOSIDE; AZTREONAM; CARBAPENEM; CARBAPENEMASE; CEFEPIME; CEPHALOSPORIN; COLISTIN; DORIPENEM; ERTAPENEM; FOSFOMYCIN; GENTAMICIN; GLYCOPEPTIDE; IMIPENEM; MACROLIDE; MEROPENEM; METALLO BETA LACTAMASE; MINOCYCLINE; NETILMICIN; OXACILLINASE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULBACTAM; SULTAMICILLIN; TETRACYCLINE; TIGECYCLINE; TIMENTIN; TOBRAMYCIN; UNCLASSIFIED DRUG;

ABDOMINAL INFECTION; ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL MENINGITIS; BLOODSTREAM INFECTION; CRITICALLY ILL PATIENT; CYSTIC FIBROSIS; DRUG BLOOD LEVEL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; GRAM NEGATIVE INFECTION; KLEBSIELLA PNEUMONIAE INFECTION; MENINGITIS; NONHUMAN; PSEUDOMONAS INFECTION; RECOMMENDED DRUG DOSE; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 84865150259     PISSN: 17551137     EISSN: 17551145     Source Type: Journal    
DOI: None     Document Type: Article

References (91)

1. Spellberg B, Guidos R, Gilbert D, et al., The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America, Clin Infect Dis, 2008;46:155-64.
2. Rice LB, Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE, J Infect Dis, 2008;197:1079-81.
3. Boucher HW, Talbot GH, Bradley JS, et al., Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America, Clin Infect Dis, 2009;48:1-12.
4. Peleg AY, Seifert H, Paterson DL, Acinetobacter baumannii: emergence of a successful pathogen, Clin Microbiol Rev, 2008;21:538-82.
5. Post V, Hall RM, AbaR5, a large multiple-antibiotic resistance region found in Acinetobacter baumannii, Antimicrob Agents Chemother, 2009;53:2667-71.
6. Abbo A, Carmeli Y, Navon-Venezia S, et al., Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes, Eur J Clin Microbiol Infect Dis, 2007;26:793-800.
7. Poirel L, Nordmann P, Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology, Clin Microbiol Infect, 2006;12:826-36.
8. Pfeifer Y, Wilharm G, Zander E, et al., Molecular characterization of blaNDM-1 in an Acinetobacter baumannii strain isolated in Germany in 2007, J Antimicrob Chemother, 2011;66:1998-2001.
9. Mussi MA, Limansky AS, Viale AM, Acquisition of resistance to carbapenems in multidrug-resistant clinical strains of Acinetobacter baumannii: natural insertional inactivation of a gene encoding a member of a novel family of beta-barrel outer membrane proteins, Antimicrob Agents Chemother, 2005;49:1432-40.
10. Huang L, Sun L, Xu G, Xia T, Differential susceptibility to carbapenems due to the AdeABC efflux pump among nosocomial outbreak isolates of Acinetobacter baumannii in a Chinese hospital, Diagn Microbiol Infect Dis, 2008;62:326-32.
11. Ikonomidis A, Neou E, Gogou V, et al., Heteroresistance to meropenem in carbapenem-susceptible Acinetobacter baumannii, J Clin Microbiol, 2009;47:4055-9.
12. Hung KH, Wang MC, Huang AH, et al., Heteroresistance to Cephalosporins and Penicillins in Acinetobacter baumannii, J Clin Microbiol, 2012;50:721-6.
13. Gales AC, Jones RN, Sader HS, Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09), J Antimicrob Chemother, 2011;66:2070-4.
14. Wang YF, Dowzicky MJ, In vitro activity of tigecycline and comparators on Acinetobacter spp. isolates collected from patients with bacteremia and MIC change during the Tigecycline Evaluation and Surveillance Trial, 2004 to 2008, Diagn Microbiol Infect Dis, 2010;68:73-9.
15. Esterly JS, Griffith M, Qi C, et al., Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections, Antimicrob Agents Chemother, 2011;55:4844-9.
16. Sengstock DM, Thyagarajan R, Apalara J, et al., Multidrug-resistant Acinetobacter baumannii: an emerging pathogen among older adults in community hospitals and nursing homes, Clin Infect Dis, 2010;50:1611-6.
17. Jellison TK, McKinnon PS, Rybak MJ, Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam, Pharmacotherapy, 2001;21:142-8.
18. Rodríguez-Hernández MJ, Cuberos L, Pichardo C, et al., Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains, J Antimicrob Chemother, 2001;47:479-82.
19. Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE, Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia, J Infect, 2008;56:432-6.
20. Jiménez-Mejías ME, Pachón J, Becerril B, et al., Treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin/sulbactam, Clin Infect Dis, 1997;24:932-5.
21. Li J, Rayner CR, Nation RL, et al., Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii, Antimicrob Agents Chemother, 2006;50:2946-50.
22. Rodríguez CH, Barberis C, Nastro M, et al., Impact of heteroresistance to colistin in meningitis caused by Acinetobacter baumannii, J Infect, 2012;64:119-21.
23. Kallel H, Hergafi L, Bahloul M, et al., Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study, Intensive Care Med, 2007;33:1162-7.
24. Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, et al., Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem- susceptible VAP, Clin Infect Dis, 2003;36:1111-8.
25. Liang W, Liu XF, Huang J, et al., Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients, BMC Infect Dis, 2011;11:109.
26. Falagas ME, Rafailidis PI, Kasiakou SK, et al., Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections, Clin Microbiol Infect, 2006;12:1227-30.
27. Falagas ME, Rafailidis PI, Ioannidou E, et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients, Int J Antimicrob Agents, 2010;35:194-9.
28. Rattanaumpawan P, Lorsutthitham J, Ungprasert P, et al., Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria, J Antimicrob Chemother, 2010;65:2645-9.
29. Kofteridis DP, Alexopoulou C, Valachis A, et al., Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study, Clin Infect Dis, 2010;51:1238-44.
30. Kwa AL, Loh C, Low JG, et al., Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa, Clin Infect Dis, 2005;41:754-7.
31. Korbila IP, Michalopoulos A, Rafailidis PI, et al., Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study, Clin Microbiol Infect, 2009;16:1230-6.
32. Tunkel AR, Hartman BJ, Kaplan SL, et al., Practice guidelines for the management of bacterial meningitis, Clin Infect Dis, 2004;39:1267-84.
33. Giamarellou H, Poulakou G, Multidrug-resistant Gram-negative infections: what are the treatment options?, Drugs, 2009;69:1879-901.
34. Hackel M, Hoban D, Badal R, et al., Trends in antimicrobial resistance in Acinetobacter spp. from the European TEST programme, Presented at: 21st European Congress of Clinical Microbiology and Infectious Diseases, Milan, Italy, 10 May 2011.
35. Schafer JJ, Goff DA, Stevenson KB, Mangino JE, Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii, Pharmacotherapy, 2007;27:980-7.
36. Poulakou G, Kontopidou FV, Paramythiotou E, et al., Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens, J Infect, 2009;58:273-84.
37. Freire AT, Melnyk V, Kim MJ, et al., Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia, Diagn Microbiol Infect Dis, 2010;68:140-51.
38. Giamarellou H, Poulakou G, Pharmacokinetic and pharmacodynamic evaluation of tigecycline, Expert Opin Drug Metab Toxicol, 2011;7:1459-70.
39. Peleg AY, Potoski BA, Rea R, et al., Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report, J Antimicrob Chemother, 2007;59:128-31.
40. Burkhardt O, Rauch K, Kaever V, et al., Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint, Int J Antimicrob Agents, 2009;34:101-2.
41. Scheetz MH, Qi C, Warren JR, et al., In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii, Antimicrob Agents Chemother, 2007;51:1621-6.
42. Jones RN, Huynh HK, Biedenbach DJ, Activities of doripenem (S-4661) against drug-resistant clinical pathogens, Antimicrob Agents Chemother, 2004;48:3136-40.
43. Chastre J, Wunderink R, Prokocimer P, et al., Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study, Crit Care Med, 2008;36:1089-96.
44. Davies TA, Marie Queenan A, Morrow BJ, et al., Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09, J Antimicrob Chemother, 2011;66:2298-2307.
45. El Garch F, Bogaerts P, Bebrone C, et al., OXA-198, an acquired carbapenem-hydrolyzing class D beta-lactamase from Pseudomonas aeruginosa, Antimicrob Agents Chemother, 2011;55:4828-33.
46. Ge C, Wei Z, Jiang Y, et al., Identification of KPC-2-producing Pseudomonas aeruginosa isolates in China, J Antimicrob Chemother, 2011;66:1184-6.
47. Riera E, Cabot G, Mulet X, et al., Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem, J Antimicrob Chemother, 2011;66:2022-7.
48. Jones RN, Stilwell MG, Rhomberg PR, Sader HS, Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997-2007), Diagn Microbiol Infect Dis, 2009;65:331-4.
49. Lee JY, Song JH, Ko KS, Identification of nonclonal Pseudomonas aeruginosa isolates with reduced colistin susceptibility in Korea, Microb Drug Resist, 2011;17:299-304.
50. Kvitko CH, Rigatto MH, Moro AL, Zavascki AP, Polymyxin B versus other antimicrobials for the treatment of pseudomonas aeruginosa bacteraemia, J Antimicrob Chemother, 2011;66:175-9.
51. Durakovic N, Radojcic V, Boban A, et al., Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis, Intern Med, 2011;50:1009-13.
52. Bergen PJ, Tsuji BT, Bulitta JB, et al., Synergistic Killing of Multidrug-Resistant Pseudomonas aeruginosa at multiple Inocula by Colistin Combined with Doripenem in an In Vitro Pharmacokinetic/Pharmacodynamic Model, Antimicrob Agents Chemother, 2011;55:5685-95.
53. Aoki N, Tateda K, Kikuchi Y, et al., Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa, J Antimicrob Chemother, 2009;63:534-42.
54. Naesens R, Vlieghe E, Verbrugghe W, et al., A retrospective observational study on the efficacy of colistin by inhalation as compared to parenteral administration for the treatment of nosocomial pneumonia associated with multidrug-resistant Pseudomonas aeruginosa, BMC Infect Dis, 2011;11:317.
55. Baiocchi M, Catena V, Zago S, et al., Intrathecal colistin for treatment of multidrug resistant (MDR) Pseudomonas aeruginosa after neurosurgical ventriculitis, Infez Med, 2010;18:182-6.
56. Samonis G, Maraki S, Rafailidis PI, et al., Antimicrobial susceptibility of Gram-negative nonurinary bacteria to fosfomycin and other antimicrobials, Future Microbiol, 2010;5:961-70.
57. Falagas ME, Kastoris AC, Karageorgopoulos DE, Rafailidis PI, Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies, Int J Antimicrob Agents, 2009;34:111-20.
58. Anonymous, EUCAST_breakpoint_consultation_2_Oct_2011. Available at: www.eucast.org/uploads/media/EUCAST_breakpoint_consult ation_2_Oct_2011.pdf (accessed 16 April 2012).
59. Rodríguez-Rojas A, Maciá MD, Couce A, et al., Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections, PLoS One, 2010;5:e10193.
60. Psichogiou M, Tassios PT, Avlamis A, et al., Ongoing epidemic of blaVIM-1-positive Klebsiella pneumoniae in Athens, Greece: a prospective survey, J Antimicrob Chemother, 2008;61:59-63.
61. Giakoupi P, Maltezou H, Polemis M, et al., KPC-2-producing Klebsiella pneumoniae infections in Greek hospitals are mainly due to a hyperepidemic clone, Euro Surveill, 2009;14(21).pii:19218.
62. Struelens MJ, Monnet DL, Magiorakos AP, et al., New Delhi metallo-beta-lactamase 1-producing Enterobacteriaceae: emergence and response in Europe, Euro Surveill, 2010;15(46).pii:19716.
63. Nordmann P, Naas T, Poirel L, Global spread of Carbapenemase-producing Enterobacteriaceae, Emerg Infect Dis, 2011;17:1791-8.
64. Nordmann P, Poirel L, Walsh TR, Livermore DM, The emerging NDM carbapenemases, Trends Microbiol, 2011;19:588-95.
65. Souli M, Galani I, Antoniadou A, et al., An outbreak of infection due to beta-Lactamase Klebsiella pneumoniae Carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes, Clin Infect Dis, 2010;50:364-73.
66. Zioga A, Miriagou V, Tzelepi E, et al., The ongoing challenge of acquired carbapenemases: a hospital outbreak of Klebsiella pneumoniae simultaneously producing VIM-1 and KPC-2, Int J Antimicrob Agents, 2010;36:190-1.
67. Poirel L, Héritier C, Tolün V, Nordmann P, Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae, Antimicrob Agents Chemother, 2004;48:15-22.
68. Daikos GL, Panagiotakopoulou A, Tzelepi E, et al., Activity of imipenem against VIM-1 metallo-beta-lactamase-producing Klebsiella pneumoniae in the murine thigh infection model, Clin Microbiol Infect, 2007;13:202-5.
69. Bulik CC, Christensen H, Li P, et al., Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model, Antimicrob Agents Chemother, 2010;54:804-10.
70. Bulik CC, Nicolau DP, In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae, Antimicrob Agents Chemother, 2010;54:4112-5.
71. Bulik CC, Nicolau DP, Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae, Antimicrob Agents Chemother, 2011;55:3002-4.
72. Daikos GL, Markogiannakis A, Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?, Clin Microbiol Infect, 2011;17:1135-41.
73. Souli M, Konstantinidou E, Tzepi I, et al., Efficacy of carbapenems against a metallo-beta-lactamase-producing Escherichia coli clinical isolate in a rabbit intra-abdominal abscess model, J Antimicrob Chemother, 2011;66:611-7.
74. Pournaras S, Protonotariou E, Voulgari E, et al., Clonal spread of KPC-2 carbapenemase-producing Klebsiella pneumoniae strains in Greece, J Antimicrob Chemother, 2009;64:348-52.
75. Marchaim D, Chopra T, Perez F, et al., Outcomes and genetic relatedness of carbapenem-resistant enterobacteriaceae at Detroit medical center, Infect Control Hosp Epidemiol, 2011;32:861-71.
76. Garonzik SM, Li J, Thamlikitkul V, et al., Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients, Antimicrob Agents Chemother, 2011;55:3284-94.
77. Plachouras D, Karvanen M, Friberg LE, et al., Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria, Antimicrob Agents Chemother, 2009;53:3430-6.
78. Pournaras S, Vrioni G, Neou E, et al., Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay, Int J Antimicrob Agents, 2011;37:244-7.
79. Souli M, Rekatsina PD, Chryssouli Z, et al., Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-beta-lactamase-producing Klebsiella pneumoniae isolates?, Antimicrob Agents Chemother, 2009;53:2133-5.
80. Berçot B, Poirel L, Dortet L, Nordmann P, In vitro evaluation of antibiotic synergy for NDM-1-producing Enterobacteriaceae, J Antimicrob Chemother, 2011;66:2295-7.
81. Satlin MJ, Kubin CJ, Blumenthal JS, et al., Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine, Antimicrob Agents Chemother, 2011;55:5893-9.
82. Livermore DM, Warner M, Mushtaq S, et al., What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline, Int J Antimicrob Agents, 2011;37:415-9.
83. Gardiner D, Dukart G, Cooper A, Babinchak T, Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials, Clin Infect Dis, 2010;50:229-38.
84. Falagas ME, Maraki S, Karageorgopoulos DE, et al., Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin, Int J Antimicrob Agents, 2010;35:240-3.
85. Samonis G, Maraki S, Karageorgopoulos DE, et al., Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates, Eur J Clin Microbiol Infect Dis, 2011;31(5):695-701.
86. Souli M, Galani I, Boukovalas S, et al., In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development, Antimicrob Agents Chemother, 2011;55:2395-7.
87. Michalopoulos A, Virtzili S, Rafailidis P, et al., Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation, Clin Microbiol Infect, 2010;16:184-6.
88. Endimiani A, Hujer KM, Hujer AM, et al., ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates, Antimicrob Agents Chemother, 2009;53:4504-7.
89. Aggen JB, Armstrong ES, Goldblum AA, et al., Synthesis and spectrum of the neoglycoside ACHN-490, Antimicrob Agents Chemother, 2010;54:4636-42.
90. Stachyra T, Levasseur P, Péchereau MC, et al., In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases, J Antimicrob Chemother, 2009;64:326-9.
91. Livermore DM, Mushtaq S, Warner M, Activity of BAL30376 (monobactam BAL19764 + BAL29880 + clavulanate) versus Gram-negative bacteria with characterized resistance mechanisms, J Antimicrob Chemother, 2010;65:2382-95.